Anxiety and Sleep Disorders: Drug and Non-Pharmacologic Considerations, Psychopharmacotherapy in Depression and Best Practice

Course overview

At the conclusion of this program, the participant will be able to: Managing Anxiety and Sleep Disorders: Drug and Non-Pharmacologic Considerations-1. Describe signs and symptoms of common sleep and anxiety disorders with a focus on older adults. 2. Discuss common anxiety disorders, including the neurobiological basis of disease, clinical presentation, assessment, and approach to treatment. 3. Recognize evidence-based treatments for insomnia and common anxiety disorders, including lifestyle, behavioral, and pharmacologic interventions. 4. Identify key parameters that warrant referral to specialty care for individuals with insomnia and/or anxiety disorders. Optimizing Psychopharmacotherapy in Depression: Clinical Cases -5. Discuss pharmacologic management options within clinical cases of patients with depression. 6. Relate physiologic and pathophysiologic alterations of brain neurochemistry to symptoms of depression, including the genetic link and molecular basis of injury. 7. Apply clinical practice guidelines for antidepressant therapies. 8. Describe key parameters for medications used to treat mechanism, safety, tolerability, efficacy, cost, and simplicity of use. Best Practices in Chronic Kidney Disease: Highlights from Latest Guidelines and Expert Recommendations-9. Describe the latest evidence and expert consensus guidance for the evaluation and risk assessment of individuals with CKD. 10. Discuss medications used to delay CKD progression and manage its complications, including mechanism of action, safety, tolerability, efficacy, price, and simplicity of use. 11.) Review strategies to identify and manage cardiovascular risk in individuals with CKD. 12. Summarize key recommendations for primary care in the evaluation, prevention, and management of CKD.